GSK Expands Biopharmaceutical Manufacturing At Rockville, Maryland, Campus
The Rockville biopharmaceutical manufacturing site consists of two FDA-licensed facilities for large and small scale manufacturing, which employ more than 400 highly-skilled scientists, engineers and manufacturing and quality professionals among other specialists.
The facility is also expected to house production of a new subcutaneous form of belimumab which is currently under review with the FDA. GSK announced regulatory filings for a subcutaneous (self-injectable) formulation of belimumab, currently available as an intravenous formulation, in Europe and the US in 2016 and is expecting to hear from regulatory bodies in the second half of 2017. The subcutaneous formulation of belimumab is currently not approved for use anywhere in the world.
The $139 million investment will be used to provide additional internal capacity to increase bulk drug substance production by close to 50% at the Rockville site, to respond to increased demand, company officials said.
"Benlysta is the first medicine specifically developed and approved for SLE in over 50 years. We are so pleased that on the first day of Lupus Awareness Month we are able to announce this expansion in Rockville, increasing our ability to provide this important medicine to patients," said Sheri Mullen, Vice President, Immunology & Rare Diseases, GSK.
In earlier expansions, the company invested $50 million to continue to develop its Global Vaccines R&D Headquarters in Rockville, which opened in December 2016. Another $245 million was invested to transform its Upper Providence, Pennsylvania site into one of two major R&D hubs for GSK globally, which was announced in December 2014.
2022 Top States for Doing Business Provide an Environment for Business Growth
2022 Top States Workforce Development Programs
The New Industrial Ecosystem
The 2021 Top States for Doing Business Reflect Their Locational Advantages
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
2022 Top States Commentary: Site Selection – When You Are Good, You Win!
Location Factors in the EV Industry — “Mission Critical” or “Nice to Have”?
2022 Auto/Aero Site Guide